ESTRO Brachytherapy for Prostate Cancer 2018

Previous Page

Next Page

Page Background

• Peer review evidence based trees estimate:

RP: 24% (15-30)

EBRT: 58% (54-64%)

BT: 9.6% (6-17.9%)

• Actual utilisations rates:

RP: 13-44%

EBRT: 43-56%

BT: 1.8-10.9%